Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay.
about
A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patientsRegional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assayResidual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mLHIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.Clinical management of HIV drug resistance.Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.Evaluation of quantification of HIV-1 RNA viral load in plasma and dried blood spots by use of the semiautomated Cobas Amplicor assay and the fully automated Cobas Ampliprep/TaqMan assay, version 2.0, in Kisumu, Kenya.Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.Comparing HIV viral load assays and frequency of low level virological rebound in clinical practice.
P2860
Q28477926-18E35388-811B-4404-94E4-571FFF15AD49Q33534504-FFF74456-9F32-4CB7-8137-30A7A796A809Q33769514-5A1ABF5C-BC01-4FEB-8BAD-CC75313600B1Q33984137-CF4DBA05-BD22-4AB1-87EC-7C650A02B192Q34301929-E84440E1-A99C-4D88-BD5A-D6013EF4B0ABQ34399511-CCCF3A0D-2289-4BCD-AE60-8B15F33B7F59Q34420782-E86220D0-643C-44AE-A16B-E2828F690A3BQ34447780-00BB2250-3BC6-4E26-9675-8DBC9B8C80A8Q34482990-ED9A239A-35DA-4691-9523-2C3D7A0B2614Q35033499-E1ABE726-9EC0-4C3D-BC27-E200FCCC85A6Q35261045-C223E21F-83A6-4114-98D3-B8DAFBF94086Q35782774-6A883BF7-3C9A-418D-83A2-8FACBC7C65D5Q35842279-DAB0ECCE-6E22-4D2C-9231-E2A3E23565B6Q36509570-D321953F-EA11-498C-80CD-5BC787557E2AQ36884491-F251BC36-AEB9-43AE-B26F-341827A8904AQ37359256-CDB24709-594B-4316-A673-4720B0C00F12Q39375437-3F3D5569-09F8-45FE-8AF9-FB09EF0D7A80Q42230298-A527BCCF-1490-45D7-A867-AE9495F049E5
P2860
Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Increased frequency of HIV-1 v ...... mplicor to Cobas Taqman assay.
@en
Increased frequency of HIV-1 v ...... mplicor to Cobas Taqman assay.
@nl
type
label
Increased frequency of HIV-1 v ...... mplicor to Cobas Taqman assay.
@en
Increased frequency of HIV-1 v ...... mplicor to Cobas Taqman assay.
@nl
prefLabel
Increased frequency of HIV-1 v ...... mplicor to Cobas Taqman assay.
@en
Increased frequency of HIV-1 v ...... mplicor to Cobas Taqman assay.
@nl
P2093
P1476
Increased frequency of HIV-1 v ...... mplicor to Cobas Taqman assay.
@en
P2093
Erasmus Smit
Husam Osman
Sanjay Bhattacharya
Steve Taylor
P304
P356
10.1097/QAI.0B013E3181AA13B3
P407
P577
2009-07-01T00:00:00Z